We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+10.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$63.8B
AUM Growth
+$3.93B
(+6.6%)
Cap. Flow
-$1.01B
Cap. Flow
% of AUM
-1.58%
Top 10 Holdings %
Top 10 Hldgs %
22.75%
Holding
3,125
New
60
Increased
388
Reduced
2,521
Closed
139
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Match Group
MTCH
|
+$20M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$11.8M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$11.8M |
| 4 |
Caesars Entertainment
CZR
|
+$11.1M |
| 5 |
PROG Holdings
PRG
|
+$11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$59.2M |
| 2 |
PPLI
People Inc
PPLI
|
+$24.6M |
| 3 |
CZR
Caesars Entertainment Corporation
CZR
|
+$19.1M |
| 4 |
Teradyne
TER
|
+$16.1M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$15.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.2% |
| 2 | Healthcare | 13.87% |
| 3 | Financials | 12.55% |
| 4 | Consumer Discretionary | 11.87% |
| 5 | Communication Services | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
Galectin Therapeutics
GALT
$348M
| $68K | ﹤0.01% |
25,434
-6,365
| -20% | -$17.8K |
|
|
AGFS
2927
DELISTED
AgroFresh Solutions Inc
AGFS
| $68K | ﹤0.01% |
28,015
-9,455
| -25% | -$23.6K |
|
|
REV
2928
DELISTED
Revlon, Inc.
REV
| $68K | ﹤0.01% |
10,749
-464
| -4% | -$3.55K |
|
|
CDTX
2929
DELISTED
Cidara Therapeutics
CDTX
| $67K | ﹤0.01% |
1,178
-219
| -16% | -$15.5K |
|
2930
Savara
SVRA
$1.19B
| $66K | ﹤0.01% |
60,713
-9,850
| -14% | -$16.9K |
|
|
NYMX
2931
DELISTED
Nymox Pharmaceutical Corp
NYMX
| $65K | ﹤0.01% |
26,534
-8,305
| -24% | -$24.2K |
|
|
EXPR
2932
DELISTED
Express, Inc.
EXPR
| $63K | ﹤0.01% |
5,144
-5,633
| -52% | -$125K |
|
|
CFRX
2933
DELISTED
ContraFect Corporation
CFRX
| $62K | ﹤0.01% |
148
+9
| +6% | +$4.08K |
|
2934
Solid Biosciences
SLDB
$900M
| $58K | ﹤0.01% |
1,889
-470
| -20% | -$18K |
|
2935
Barclays
BCS
$94.1B
| $57K | ﹤0.01% |
+11,468
| New | +$63.4K |
|
|
TEF
2936
DELISTED
Telefonica
TEF
| $56K | ﹤0.01% |
19,189
+711
| +4% | +$2.5K |
|
2937
Pixelworks
PXLW
$41.6M
| $55K | ﹤0.01% |
2,256
-733
| -25% | -$23.7K |
|
2938
Rimini Street
RMNI
$471M
| $55K | ﹤0.01% |
17,020
-3,425
| -17% | -$15.7K |
|
2939
ReposiTrak
TRAK
$159M
| $54K | ﹤0.01% |
10,923
-1,940
| -15% | -$9.04K |
|
2940
Custom Truck One Source
CTOS
$2.37B
| $53K | ﹤0.01% |
12,670
-2,810
| -18% | -$10.9K |
|
2941
NLI Holdings
NL
$317M
| $53K | ﹤0.01% |
12,538
-6,571
| -34% | -$23.6K |
|
|
SBBP
2942
DELISTED
Strongbridge Biopharma plc.
SBBP
| $53K | ﹤0.01% |
25,141
-8,645
| -26% | -$29.1K |
|
2943
Lloyds Banking Group
LYG
$91.3B
| $50K | ﹤0.01% |
38,369
+14,930
| +64% | +$20.9K |
|
2944
VolitionRx Ltd
VNRX
$9.34M
| $50K | ﹤0.01% |
779
-319
| -29% | -$21.7K |
|
2945
Avalo Therapeutics
AVTX
$983M
| $49K | ﹤0.01% |
7
-1
| -13% | -$7.52K |
|
|
SCTL
2946
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $48K | ﹤0.01% |
22,676
-3,775
| -14% | -$12.4K |
|
|
IMDX
2947
Insight Molecular Diagnostics
IMDX
$156M
| $47K | ﹤0.01% |
1,702
-153
| -8% | -$4.39K |
|
2948
Organogenesis Holdings
ORGO
$239M
| $47K | ﹤0.01% |
12,328
-3,495
| -22% | -$13.8K |
|
2949
Target Hospitality
TH
$1.64B
| $47K | ﹤0.01% |
38,184
-825
| -2% | -$1.18K |
|
2950
Nokia
NOK
$52.3B
| $44K | ﹤0.01% |
11,305
| – | – |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2020 Portfolio in Review
As of Q3 2020, RhumbLine Advisers held 3,125 positions worth $63.8B, up 6.6% from $59.9B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
RhumbLine Advisers's Q3 2020 filing shows 60 new, 388 increased, 2,521 reduced and 139 closed positions. Its largest new stake was PROG Holdings: 245,531 shares worth $11.8M. The largest sale was Apple, an estimated $59.2M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.
- RhumbLine Advisers's largest Q3 2020 buy was PROG Holdings: 245,531 shares worth $11.8M.
- RhumbLine Advisers added most to Match Group in Q3 2020, an estimated $20M increase.
- RhumbLine Advisers's biggest Q3 2020 reduction was Apple, cutting an estimated $59.2M.
- RhumbLine Advisers fully exited Caesars Entertainment Corporation in Q3 2020, selling an estimated $19.1M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $63.8B portfolio in Q3 2020.
- RhumbLine Advisers opened 60 new positions and closed 139 in Q3 2020.
- RhumbLine Advisers's portfolio value rose 6.6% quarter-over-quarter to $63.8B.
Based on RhumbLine Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.